<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2011246286
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LAYAL 5 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVOCETIRIZINE DIHYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        OTC
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        7.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jordan Sweden Medical and Sterilization Co." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jordan Sweden Medical and Sterilization Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 679]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AL-DAWAA MEDICAL SERVICES CO. LTD
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jordan Sweden Medical and Sterilization Co.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R06AE09 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Layal tablets contain the active substance Levocetirizine Dihydrochloride.</p><p>Layal tablets is an antiallergic medication.</p><p>Layal tablets are used to treat the signs of illness (symptoms) associated with:</p><p>&bull; Allergic rhinitis (including persistent allergic rhinitis).</p><p>&bull; Nettle rash (urticaria).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>A. Do not take Layal tablets:</p><p>&bull; If you are allergic to Levocetirizine Dihydrochloride, Cetirizine, Hydroxyzine or any of the other ingredients of this medicine (listed in section 6).</p><p>&bull; If you have a severe impairment of kidney function (severe renal failure with creatinine clearance below 10 ml/min).</p><p>B. Take special care with Layal tablets:</p><p>Talk to your doctor or pharmacist before taking Layal.</p><p>If you are likely to be unable to empty your bladder (with conditions such as spinal cord injury or enlarged prostate), ask your doctor for advice.</p><p>If you are scheduled for allergy testing, ask your doctor if you should stop taking Layal for several days before testing. This medicine may affect your allergy test results.</p><p>Children:</p><p>The use of Layal Tablets is not recommended in children less than 6 years since the tablets do not allow for dose adaptation.</p><p>C. Taking other medicines with Layal tablets:</p><p>Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p>D. Taking Layal tablets with food and drink:</p><p>Caution is advised if Layal is taken at the same time as alcohol or other agents acting on the brain.</p><p>In sensitive patients, the concurrent administration of Layal and alcohol or other agents acting on the brain may cause additional reductions in alertness and impairment of performance.</p><p>Layal can be taken with or without food.</p><p>E. Pregnancy and breast-feeding:</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>F. Driving and using machines:</p><p>Some patients being treated with Layal tablets may experience somnolence / drowsiness, tiredness and exhaustion. Use caution when driving or operating machinary untill you know how this medicine affects you. However, special tests have revealed no impairment of mental alertness, the ability to react or the ability to drive in healthy test persons after taking Levocetirizine in the recommended dosage.</p><p>G.Important information about some of the ingredients of Layal tablets:</p><p>Layal tablets contain lactose, if you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>Layal tablets also contain sunset yellow as coloring agent which may cause allergic reactions.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Layal exactly as your doctor or pharmacist has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose for adults and children aged 6 years and over is one tablet daily.</p><p>Special dosage instructions for specific populations:</p><p>Renal and hepatic impairment:</p><p>Patients with impaired kidney function may be given a lower dose according to the severity of their kidney disease, and in children the dose will also be chosen on the basis of body weight; the dose will be determined by your doctor.</p><p>Patients who have severe impairment of kidney function must not take Layal.</p><p>Patients who only have impaired liver function should take the usual prescribed dose.</p><p>Patients who have both impaired liver and kidney function may be given a lower dose depending on the se-verity of the kidney disease, and in children the dose will also be chosen on the basis of body weight; the dose will be determined by your doctor.</p><p>Elderly patients aged 65 years and above:</p><p>No adaptation of the dose is necessary in elderly patients, provided their renal function is normal.</p><p>Use in children:</p><p>Layal tablets is not recommended for children under 6 years of age.</p><p>How and when should you take Layal tablets?</p><p>For oral use only.</p><p>Layal tablets should be swallowed whole with water and may be taken with or without food.</p><p>How long should you take Layal tablets?</p><p>The duration of use depends on the type, duration and course of your complaints and is determined by your physician.</p><p>A.If you take more Layal tablets than you should:</p><p>If you take more Layal tablets than you should, somnolence can occur in adults. Children may initially show excitation and restlessness followed by somnolence.</p><p>If you think you have taken an overdose of Layal, tell your doctor who will then decide what action should be taken.</p><p>B.If you forget to take your Layal tablets:</p><p>If you forget to take Layal, or if you take a dose lower than that prescribed by your doctor, do not take a double dose to make up for a forgotten dose. Take your next dose at your normal time.</p><p>C.If you stop taking Layal tablets:</p><p>Stopping treatment should have no negative effects. However, rarely pruritus (intense itching) may occur if you stop taking Layal, even if those symptoms were not present before treatment initiation. The symptoms may resolve spontaneously. In some cases, the symptoms may be intense and may require treatment to be restarted. The symptoms should resolve when the treatment is restarted.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Layal can cause side effects, although not everybody gets them.</p><p>Common side effects (may affect up to 1 in 10 people):</p><p>Dry mouth, headache, tiredness and somnolence / drowsiness.</p><p>Uncommon side effects (may affect up to 1 in 100 people):</p><p>Exhaustion and abdominal pain.</p><p>Not known side effects (frequency cannot be estimated from the available data):</p><p>Other side effects such as palpitations, increased heart rate, fits, pins and needles, dizziness, syncope, tremor, dysgeusia (distortion of the sense of taste), sensation of rotation or movement, visual disturbances, blurred vision, painful or difficult urination, inability to completely empty the bladder, oedema, pruritus (itchiness), rash, urticaria (swelling, redness and itchiness of the skin), skin eruption, shortness of breath, weight increase, muscular pain, joint pain, aggressive or agitated behaviour, hallucination, depression, insomnia, recurring thoughts of or preoccupation with suicide, hepatitis, abnormal liver function, vomiting, increased appetite, nausea and diarrhoea have also been reported.</p><p>Pruritus (intense itching) upon discontinuation.</p><p>At the first signs of a hypersensitivity reaction, stop taking Layal and tell your doctor.</p><p>Hypersensitivity reaction symptoms may include: swelling of the mouth, tongue, face and/or throat, breathing or swallowing difficulties (chest tightness or wheezing) hives, sudden fall in blood pressure leading to collapse or shock, which may be fatal.</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, talk to your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the reach and sight of children.</p><p>&bull; Do not use Layal after the expiry date which is stated on the label and carton.&nbsp;&nbsp;</p><p>&bull; This medicinal product does not require any special storage conditions.</p><p>&bull; Do not use any Layal pack that is damaged or shows signs of tampering.</p><p>&bull; Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Each tablet contains 5 mg of Levocetirizine Dihydrochloride.</p><p>The other ingredients are: Lactose Monohydrate, Maize Starch, Colloidal Silicon Dioxide, Magnesium Stearate and Sunset Yellow.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pharmaceutical form: Tablet.
Pack size: 10 & 30 Tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jordan Sweden Medical and Sterilization Company (Joswe-medical)</p><p>P.O. Box 851831 Amman 11185 Jordan</p><p>E-mail: joswe@go.com.jo</p><p>www.joswe.com</p><p>Tel: +962 6 5859765, +962 6 5728327</p><p>Fax: +962 6 5814526, +962 6 5728326</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 08/2017; Revision number R0. 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>تحتوي أقراص ليال على ليفوسيتيريزين دايهيدروكلورايد كمادة فعالة.</p><p>أقراص ليال هي من الأدوية المضادة للحساسية.</p><p>تستخدم أقراص ليال لعلاج علامات (أعراض) المرض المتعلقة ب:</p><p>&bull;حساسية الأنف (بما في ذلك التهاب الأنف التحسسي).</p><p>&bull;طفح القراص (الشرى).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>أ. لا تتناول أقراص ليال:</p><p>&bull;إذا كنت تعاني من الحساسية ضد ليفوسيتيريزين دايهيدروكلورايد، سيتيريزين، هايدروكسيزين أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p>&bull;إذا كان لديك ضعف شديد في وظائف الكلى (الفشل الكلوي الحاد مع تصفية الكرياتينين أقل من 10 مل / دقيقة).</p><p>ب. أخذ الحيطة والحذر عند تناول أقراص ليال:</p><p>تحدث إلى طبيبك أو الصيدلاني قبل أن تتناول ليال.</p><p>إذا كنت غير قادر على تفريغ المثانة (المصابين بأمراض مثل إصابات الحبل الشوكي أو تضخم البروستات)، اسأل طبيبك للحصول على المشورة.</p><p>إذا كان من المقرر إجراء اختبار الحساسية لك، اسأل طبيبك إذا كان عليك التوقف عن تناول ليال لعدة أيام قبل الاختبار. هذا الدواء قد يؤثر على نتائج اختبار الحساسية.</p><p>الأطفال:</p><p>لا ينصح استخدام ليال أقراض من قبل الأطفال أقل من 6 سنوات، و ذلك لأن الشكل الصيدلاني &quot;أقراص&quot; لا يسمح بإعطاء الجرعة المناسبة لهم.</p><p>ج. تناول أدوية أخرى مع أقراص ليال:</p><p>أخبر طبيبك أو الصيدلاني إذا كنت تتناول أو تناولت حديثا&quot; أي أدوية أخرى، وتشمل الأدوية&nbsp; التي يتم صرفها بدون وصفة طبية.</p><p>د. تناول أقراص ليال مع الطعام والشراب:</p><p>ينصح الحذر إذا تم تناول ليال في نفس الوقت الكحول أو غيرها من المواد التي تؤثر على الدماغ.</p><p>في المرضى الحساسين، تناول ليال بشكل متزامن مع الكحول أو غيرها من المواد التي تؤثر على الدماغ قد يسبب تخفيض إضافي في اليقظة وضعف الأداء.</p><p>يمكن تناول ليال مع الطعام أو بدونه.</p><p>ه.&nbsp; الحمل و الإرضاع:</p><p>إذا كنت حامل أو مرضع ، أو من الممكن أن تكوني حامل أو تخططين للإنجاب، يجب عليك استشارة الطبيب قبل تناولك لهذا الدواء.</p><p>و. القيادة وتشغيل الآلات:</p><p>بعض المرضى الذين يتعالجون باستخدام ليال قد يواجهون النعاس والدوار والتعب والإرهاق. توخى الحذر عند القيادة أو استخدام الآلات حتى تعرف كيف يؤثر هذا الدواء عليك. ومع ذلك، فقد كشفت اختبارات خاصة عدم ضعف اليقظة العقلية والقدرة على الاستجابة أو القدرة على القيادة في الأشخاص الأصحاء الذين خضعو للاختبارات بعد أخذ ليفوسيتيريزين حسب الجرعة الموصى بها.</p><p>ز.معلومات مهمة عن بعض مكونات ليال:</p><p>أقراص ليال تحتوي على اللاكتوز، إذا أخبرك&nbsp; طبيبك بأنك من الممكن أن لا تتحمل بعض السكريات، اتصل بطبيبك قبل تناولك لهذا الدواء.</p><p>تحتوي أقراص ليال أيضا على sunset yellow&nbsp; كمادة ملونة والتي من الممكن أن تسبب تفاعلات تحسسية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>دائما قم بتناول ليال تماما كما أخبرك الطبيب أو الصيدلاني. إذا كنت غير متأكد بإمكانك الرجوع الى الطبيب أو الصيدلاني.</p><p>الجرعة الموصى بها للبالغين والأطفال في عمر 6 سنوات وأكثر هي قرص واحد يومياً.</p><p>تعليمات الجرعات الخاصة لفئة معينة من الأشخاص:</p><p>القصور الكلوي و الكبدي:</p><p>المرضى الذين يعانون من قصور في وظائف الكلى يمكن إعطائهم جرعة أقل وفقا لشدة مرض الكلى، و بالنسبة للأطفال سيتم اختيار الجرعة على أساس وزن الجسم، وسيتم تحديد الجرعة من قبل الطبيب.</p><p>يجب عدم تناول ليال من قبل المرضى الذين لديهم ضعف شديد في وظائف الكلى.</p><p>المرضى الذين يعانون فقط من ضعف في وظائف الكبد يجب عليهم تناول الجرعة الموصوفة عادة.</p><p>المرضى الذين يعانون من قصور في وظائف الكبد و الكلى معا&quot; يمكن إعطائهم جرعة أقل وفقا&quot; لشدة مرض الكلى، و بالنسبة للأطفال سيتم اختيار الجرعة على أساس وزن الجسم، وسيتم تحديد الجرعة من قبل الطبيب.</p><p>المرضى كبار السن الذين تبلغ أعمارهم 65 سنة و ما فوق:</p><p>لا تغيير ضروري على الجرعة في المرضى المسنين، شريطة أن تكون وظائف الكلى طبيعية.</p><p>الإستخدام من قبل الأطفال:</p><p>لا ينصح استخدام ليال أقراص من قبل الأطفال أقل من 6 سنوات.</p><p>كيف و متى يجب أن تتناول أقراص ليال؟</p><p>للاستخدام عن طريق الفم فقط.</p><p>يجب تناول أقراص ليال مع الماء، ويمكن تناول ليال بغض النظر مع الطعام أو بدونه.</p><p>ما هي المدة الزمنية لتناول أقراص ليال؟</p><p>مدة الاستخدام تعتمد على نوع، و مدة و طبيعة الشكوى، و هذا يتم تحديده من قبل الطبيب المعالج.</p><p>أ&zwnj;.إذا كنت تتناول جرعة أقراص ليال أكثر من اللازم:</p><p>إذا تناولت أقراص ليال أكثر مما يجب، يمكن أن يشعر البالغين بالنعاس. الأطفال قد يظهر عليهم في البداية الإثارة والاسترخاء الذي يتبعه النعاس.</p><p>إذا كنت تعتقد أنك أخذت جرعة زائدة من ليال، أخبر طبيبك الذي سوف يقرر ما هي الإجراءات التي ينبغي اتخاذها.</p><p>ب. إذا نسيت تناول أقراص ليال:</p><p>إذا كنت قد نسيت تناول الجرعة، أو إذا تناولت جرعة أقل من التي وصفها لك طبيبك، لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية. خذ الجرعة التالية في وقتها المعتاد.</p><p>ج&zwnj;.إذا توقفت عن تناول أقراص ليال:</p><p>وقف العلاج يجب أن لا يكون له آثار سلبية.ومع ذلك، إذا توقفت عن تناول ليال نادرا ما قد تحدث حكة (حكة شديدة) ، حتى لو لم تكن هذه الأعراض موجودة قبل البدء بالعلاج. قد تزول الأعراض بشكل تلقائي. في بعض الحالات، قد تكون الأعراض حادة وقد تتطلب إعادة العلاج. يجب أن تزول الأعراض عند إعادة العلاج.</p><p>إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء قم بسؤال طبيبك أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن لهذا الدواء أن يسبب آثار جانبية على الرغم من عدم حدوثها لدى الجميع.</p><p>آثارجانبية شائعة (من الممكن أن تصيب لغاية شخص لكل 10 أشخاص):</p><p>جفاف الفم، والصداع، و التعب والنعاس والدوخة.</p><p>آثار جانبية غير شائعة (من الممكن أن تصيب لغاية شخص لكل 100 شخص):</p><p>الإرهاق وآلام في البطن.</p><p>آثار جانبية غير معروفة (لا يمكن تقدير تكرارها من البيانات المتاحة):</p><p>الآثار الجانبية الأخرى مثل الخفقان، زيادة معدل ضربات القلب، نوبات، الوخز، الدوخة، الإغماء، الرعاش، خلل في حاسة التذوق، الإحساس بالدوران، اضطرابات بصرية، عدم وضوح في الرؤية، ألم أو صعوبة عند التبول، عدم القدرة على إفراغ المثانة تماماً، وذمة، حكة، طفح جلدي، الشرى (تورم واحمرار وحكة في الجلد)، ضيق في التنفس، زيادة الوزن، آلام العضلات، آلام المفاصل، السلوك العدواني، هلوسة، الاكتئاب، الأرق، الأفكار المتكررة في الانتحار، التهاب الكبد، وظائف الكبد غير الطبيعية، القيء، زيادة الشهية، الغثيان، وكما تم الإبلاغ عن الإصابة بالإسهال.</p><p>الحكة (حكة شديدة) عند التوقف عن تناول العلاج.</p><p>في أولى بوادر ردود فعل فرط الحساسية، توقف عن تناول ليال و أخبر طبيبك بذلك.</p><p>ويمكن أن تشمل أعراض فرط الحساسية: تورم في الفم و اللسان و الوجه و/ أو الحلق، صعوبة في التنفس أو البلع (ضيق الصدر أو الصفير)، هبوط مفاجئ في ضغط الدم الذي يؤدي إلى الانهيار أو الصدمة، والتي قد تكون قاتلة.</p><p>اذا تفاقم أحد هذه الأعراض الجانبية، أو إذا لاحظت أي أعراض جانبية أخرى لم يرد ذكرها في هذه النشرة، يرجى إخبار الطبيب أو الصيدلاني</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; يحفظ بعيدا عن متناول الأطفال.</p><p>&bull; لا تستخدم ليال بعد إنتهاء فترة الصلاحية المذكورة على اللاصق الداخلي والعبوة الخارجية.</p><p>&bull; لا يحتاج هذا المنتج الطبي إلى ظروف تخزين خاصة.</p><p>&bull; لا تستخدم ليال عند ملاحظة أي علامة تلف عليه.</p><p>&bull; يحفظ بدرجة حرارة أقل من 30 oم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>كل قرص يحتوي على 5 ملغم ليفوسيتيريزين دايهيدروكلورايد.</p><p>المكونات الأخرى هي: لاكتوز أحادي الماء، نشا الذرة، كوللويدال سيليكون دايوكسيد، ستيرات المغنيسيوم، لون أصفر</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>الشكل الصيدلاني: أقراص.</p><p>سعة العبوة: عبوة 10 أقراص و عبوة 30 قرص</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الشركة الأردنية السويدية للمنتجات الطبية و التعقيم.</p><p>صندوق بريد 851831&nbsp; عمان 11185&nbsp; الأردن</p><p>الايميل: joswe@go.com.jo</p><p>www.joswe.com</p><p>هاتف:&nbsp; 5728327 6 962+ ، 5859765 6 962</p><p>فاكس:&nbsp;&nbsp; 5728326 6 962+ ، 5814526 6 962</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             تمت مراجعة هذه النشرة في 08/2017؛ رقم المراجعة R0
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Layal 5mg Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 5mg of Levocetirizine Dihydrochloride. Excipients with known effect: 65.0mg Lactose Monohydrate For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet. 
Orange to light orange tablet blemished with white and orange.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Layal 5 mg tablets are indicated in the symptomatic treatment of allergic rhinitis (including persistent allergic rhinitis) and urticaria in adults and children aged 6 years and above</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Adults and adolescents 12 years and above:</p><p>The daily recommended dose is 5 mg (1 tablet).</p><p><em>Elderly</em></p><p>Adjustment of the dose is recommended in elderly patients with moderate to severe renal impairment (see Renal impairment below).</p><p>Renal impairment</p><p>The dosing intervals must be individualised according to renal function. Refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient&#39;s creatinine clearance (CLcr) in ml/min is needed. The CLcr (ml/min) may be estimated from serum creatinine (mg/dl) determination using the following formula:<br />CLcr =&nbsp;<u>[140 - age{years)]* weight(kg)</u> (*0.85 forwomen )</p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 72*serum creaiinim{mg / dl)</p><p>Dosing adjustments for patients with impaired renal function:</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="width:148px">Group</td><td style="width:176px">Creatinine clearance (ml/min)</td><td style="width:175px">Dosage and frequency</td></tr><tr><td style="width:148px">Normal</td><td style="width:176px">&ge; 80</td><td style="width:175px">1 tablet once daily</td></tr><tr><td style="width:148px">Mild</td><td style="width:176px">50 &ndash; 79</td><td style="width:175px">1 tablet once daily</td></tr><tr><td style="width:148px">Moderate</td><td style="width:176px">30 &ndash; 49</td><td style="width:175px">1 tablet once every 2 days</td></tr><tr><td style="width:148px">Severe</td><td style="width:176px">&lt; 30</td><td style="width:175px">1 tablet once every 3 days</td></tr><tr><td style="width:148px">End-stage renal disease -<br />Patients undergoing dialysis</td><td style="width:176px">&lt; 10</td><td style="width:175px">Contra-indicated</td></tr></tbody></table><p>In paediatric patients suffering from renal impairment, the dose will have to be adjusted on an<br />individual basis taking into account the renal clearance of the patient and his body weight.<br />There are no specific data for children with renal impairment.<br /><em>Hepatic impairment:</em><br />No dose adjustment is needed in patients with solely hepatic impairment. In patients with<br />hepatic impairment and renal impairment, adjustment of the dose is recommended (see Renal<br />impairment above).<br /><em>Paediatric population</em><br />Children aged 6 to 12 years:<br />The daily recommended dose is 5 mg (1 film-coated tablet).<br />For children aged 2 to 6 years no adjusted dosage is possible with the tablet formulation. It is<br />recommended to use a pediatric formulation of levocetirizine.<br /><u>Method of administration</u><br />The tablet must be taken orally, swallowed whole with liquid and may be taken with or without<br />food. It is recommended to take the daily dose in one single intake.<br />Duration of use:<br />Intermittent allergic rhinitis (symptoms experienced for less than four days a week or for less<br />than four weeks a year) has to be treated according to the disease and its history; it can be<br />stopped once the symptoms have disappeared and can be restarted again when symptoms<br />reappear. In case of persistent allergic rhinitis (symptoms experienced for more than four days<br />a week or for more than four weeks a year), continuous therapy can be proposed to the patient<br />during the period of exposure to allergens.<br />There is clinical experience with the use of levocetirizine for treatment periods of at least 6<br />months. In chronic urticaria and chronic allergic rhinitis, there is clinical experience of use of<br />cetirizine (racemate) for up to one year.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, to cetirizine, to hdroxyzine, to any other piperazine
derivatives or to any of the other excipients listed in section 6.1.
Severe renal impairment at less than 10 ml/min creatinine clearance.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Precaution is recommended with concurrent intake of alcohol (see section 4.5).<br />Caution should be taken in patients with predisposing factors of urinary retention (e.g. spinal<br />cord lesion, prostatic hyperplasia) as levocetirizine may increase the risk of urinary retention.<br />Response to allergy skin tests are inhibited by antihistamines and a wash-out period (of 3 days)<br />is required before performing them.</p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or<br />glucose-galactose malabsorption should not take this medicine.<br />Pruritus may occur when levocetirizine is stopped even if those symptoms were not present<br />before treatment initiation. The symptoms may resolve spontaneously. In some cases, the</p><p>symptoms may be intense and may require treatment to be restarted. The symptoms should<br />resolve when the treatment is restarted.</p><p><u>Paediatric population</u><br />The use of the film-coated tablet formulation is not recommended in children aged less than 6<br />years since this formulation does not allow for appropriate dose adaptation. It is recommended<br />to use a paediatric formulation of levocetirizine.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed with levocetirizine (including no studies with<br />CYP3A4 inducers); studies with the racemate compound cetirizine demonstrated that there<br />were no clinically relevant adverse interactions (with antipyrine, azithromycin, cimetidine,<br />diazepam, erythromycin, glipizide, ketoconazole and pseudoephedrine). A small decrease in<br />the clearance of cetirizine (16%) was observed in a multiple dose study with theophylline (400<br />mg once a day); while the disposition of theophylline was not altered by concomitant cetirizine<br />administration.<br />In a multiple dose study of ritonavir (600 mg twice daily) and cetirizine (10 mg daily), the<br />extent of exposure to cetirizine was increased by about 40% while the disposition of ritonavir<br />was slightly altered (-11%) further to concomitant cetirizine administration.<br />The extent of absorption of levocetirizine is not reduced with food, although the rate of<br />absorption is decreased.<br />In sensitive patients, the concurrent administration of cetirizine or levocetirizine and alcohol or<br />other CNS depressants may cause additional reductions in alertness and impairment of<br />performance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u><br />There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of<br />levocetirizine in pregnant women. However, for cetirizine, the racemate of levocetirizine, a<br />large amount of data (more than 1000 pregnancy outcomes) on pregnant women indicate no<br />malformative or feto/ neonatal toxicity. Animal studies do not indicate direct or indirect<br />harmful effects with respect to pregnancy, embryo/fetal development, parturition or postnatal<br />development (see section 5.3).<br />The use of levocetirizine may be considered during pregnancy, if necessary.</p><p><u>Breast-feeding</u><br />Cetirizine, the race mate of levocetirizine, has been shown to be excreted in human. Therefore,<br />the excretion of levocetirizine in human milk is likely. Adverse reactions associated with<br />levocetirizine may be observed in breastfed infants. Therefore, caution should be exercised<br />when prescribing levocetirizine to lactating women.<br /><u>Fertility</u><br />For levocetirizine no clinical data are available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Comparative clinical trials have revealed no evidence that levocetirizine at the recommended<br />dose impairs mental alertness, reactivity or the ability to drive.<br />Nevertheless, some patients could experience somnolence, fatigue and asthenia under therapy<br />with levocetirizine. Therefore, patients intending to drive, engage in potentially hazardous<br />activities or operate machinery should take their response to the medicinal product into<br />account.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Clinical studies</u><br />Adults and adolescents above 12 years of age<br />In therapeutic studies in women and men aged 12 to 71 years, 15.1% of the patients in the<br />levocetirizine 5 mg group had at least one adverse drug reaction compared to 11.3% in the<br />placebo group. 91.6 % of these adverse drug reactions were mild to moderate.<br />In therapeutic trials, the dropout rate due to adverse events was 1.0% (9/935) with<br />levocetirizine 5 mg and 1.8% (14/771) with placebo.<br />Clinical therapeutic trials with levocetirizine included 935 subjects exposed to the medicinal<br />product at the recommended dose of 5 mg daily. From this pooling, following incidence of<br />adverse drug reactions were reported at rates of 1% or greater (common: &ge;1/100 to &lt;1/10)<br />under levocetirizine 5 mg or placebo:</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="width:150px">Preferred Term<br />(WHOART)</td><td style="text-align:center; width:171px">Placebo<br />(n =771)</td><td style="text-align:center; width:178px">Levocetirizine 5 mg<br />(n = 935)</td></tr><tr><td style="width:150px">Headache</td><td style="text-align:center; width:171px">25 (3.2%)</td><td style="text-align:center; width:178px">24 (2.6%)</td></tr><tr><td style="width:150px">Somnolence</td><td style="text-align:center; width:171px">11 (1.4%)</td><td style="text-align:center; width:178px">49 (5.2%)</td></tr><tr><td style="width:150px">Mouth dry</td><td style="text-align:center; width:171px">12 (1.6%)</td><td style="text-align:center; width:178px">24 (2.6%)</td></tr><tr><td style="width:150px">Fatigue</td><td style="text-align:center; width:171px">9 (1.2%)</td><td style="text-align:center; width:178px">23 (2.5%)</td></tr></tbody></table><p>Further uncommon incidences of adverse reactions (uncommon &ge;1/1,000 to &lt;1/100) like<br />asthenia or abdominal pain were observed.<br />The incidence of sedating adverse drug reactions such as somnolence, fatigue, and asthenia<br />was altogether more common (8.1%) under levocetirizine 5 mg than under placebo (3.1%).</p><p><strong><u>Paediatric population</u></strong><br />In two placebo-controlled studies in paediatric patients aged 6-11 months and aged 1 year to<br />less than 6 years, 159 subjects were exposed to levocetirizine at the dose of 1.25 mg daily for 2<br />weeks and 1.25mg twice daily respectively. The following incidence of adverse drug reactions<br />was reported at rates of 1% or greater under levocetirizine or placebo.</p><table border="1" cellspacing="1" cellpadding="1" style="width:680px"><tbody><tr><td style="width:374px"><strong>System Organ Class and Preferred Term</strong></td><td style="width:122px"><strong>Placebo (n=83)</strong></td><td style="width:181px"><strong>Levocetirizine (n=159)</strong></td></tr><tr><td style="width:374px"><strong>Gastrointestinal disorders</strong></td><td style="width:122px">&nbsp;</td><td style="width:181px">&nbsp;</td></tr><tr><td style="width:374px">Diarrhoea</td><td style="text-align:center; width:122px">0</td><td style="text-align:center; width:181px">3(1.9%)</td></tr><tr><td style="width:374px">Vomiting</td><td style="width:122px">1(1.2%)</td><td style="width:181px">1(0.6%)</td></tr><tr><td style="width:374px">Constipation</td><td style="width:122px">0</td><td style="width:181px">2(1.3%)</td></tr><tr><td style="width:374px"><strong>Nervous system disorders</strong></td><td style="width:122px">&nbsp;</td><td style="width:181px">&nbsp;</td></tr><tr><td style="width:374px">Somnolence</td><td style="width:122px">2(2.4%)</td><td style="width:181px">3(1.9%)</td></tr><tr><td style="width:374px"><strong>Psychiatric disorders</strong></td><td style="width:122px">&nbsp;</td><td style="width:181px">&nbsp;</td></tr><tr><td style="width:374px">Sleep disorder</td><td style="width:122px">0</td><td style="width:181px">2(1.3%)</td></tr></tbody></table><p>In children aged 6-12 years double blind placebo controlled studies were performed where 243<br />children were exposed to 5 mg levocetirizine daily for variable periods ranging from less than<br />1 week to 13 weeks. The following incidence of adverse drug reactions was reported at rates of<br />1% or greater under levocetirizine or placebo.</p><table border="1" cellspacing="1" cellpadding="1" style="width:581px"><tbody><tr><td style="width:217px"><strong>Preferred Term</strong></td><td style="text-align:center; width:179px"><strong>Placebo (n=240)</strong></td><td style="text-align:center; width:180px"><strong>Levocetirizine 5mg (n=243)</strong></td></tr><tr><td style="width:217px">Headache</td><td style="text-align:center; width:179px">5(2.1%)</td><td style="text-align:center; width:180px">2(0.8%)</td></tr><tr><td style="width:217px">Somnolence</td><td style="text-align:center; width:179px">1(0.4%)</td><td style="text-align:center; width:180px">7(2.9%)</td></tr></tbody></table><p><u>Post-marketing experience</u><br />Adverse reactions from post-marketing experience are per System Organ Class and per<br />frequency. The frequency is defined as follows: very common (&ge;1/10); common (&ge;1/100 to<br />&lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000),<br />not known (cannot be estimated from the available data)</p><p>&bull; Immune system disorders:<br />Not known: hypersensitivity including anaphylaxis<br />&bull; Metabolism and nutrition disorders:<br />Not known: increased appetite<br />&bull; Psychiatric disorders:<br />Not known: aggression, agitation, hallucination, depression, insomnia, suicidal ideation<br />&bull; Nervous system disorders:</p><p>Not known: convulsion, paraesthesia, dizziness, syncope, tremor, dysgeusia, Movement<br />disorders (including dystonia and oculogyric crisis tic, myoclonus, extrapyramidal symptoms<br />&bull; Ear and labyrinth disorders:<br />Not known: vertigo<br />&bull; Eyes disorders:<br />Not known: visual disturbances, blurred vision<br />&bull; Cardiac disorders:<br />Not known: palpitations, tachycardia<br />&bull; Respiratory, thoracic and mediastinal disorders:<br />Not known: dyspnoea<br />&bull; Gastrointestinal disorders:<br />Not known: nausea, vomiting, diarrhoea<br />&bull; Hepatobiliary disorders:<br />Not known: hepatitis</p><p>Renal and urinary disorders:<br />Not known: dysuria, urinary retention<br />&bull; Skin and subcutaneous tissue disorders:<br />Not known: angioneurotic oedema, fixed drug eruption, pruritus, rash, urticaria<br />&bull; Musculoskeletal, connective tissues, and bone disorders:<br />&bull; Not known: myalgia, arthralgia<br />&bull; General disorders and administration site conditions:<br />Not known: oedema<br />&bull; Investigations:<br />Not known: weight increased, abnormal liver function tests</p><p><u>Description of selected adverse reactions</u><br />After levocetirizine discontinuation, pruritus has been reported.</p><p>To reports any side effect (s):</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u><br />Symptoms of overdose may include drowsiness in adults. In children, agitation and restlessness<br />may initially occur, followed by drowsiness.<br /><u>Management of overdoses</u><br />There is no known specific antidote to levocetirizine.<br />Should overdose occur, symptomatic or supportive treatment is recommended. Gastric lavage<br />may be considered shortly after ingestion of the drug. Levocetirizine is not effectively removed<br />by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antihistamine for systemic use, piperazine derivatives,<br />ATC code: R06A E09.<br /><u>Mechanism of action</u><br />Levocetirizine, the (R) enantiomer of cetirizine, is a potent and selective antagonist of<br />peripheral H1-receptors.<br />Binding studies revealed that levocetirizine has high affinity for human H1-receptors (Ki = 3.2<br />nmol/l). Levocetirizine has an affinity 2-fold higher than that of cetirizine (Ki = 6.3 nmol/l).<br />Levocetirizine dissociates from H1-receptors with a half-life of 115 &plusmn; 38 min.</p><p>After single administration, levocetirizine shows a receptor occupancy of 90% at 4 hours and<br />57% at 24 hours.<br />Pharmacodynamic studies in healthy volunteers demonstrate that, at half the dose,<br />levocetirizine has comparable activity to cetirizine, both in the skin and in the nose.</p><p><u>Pharmacodynamic effects</u><br />The pharmacodynamic activity of levocetirizine has been studied in randomised, controlled<br />trials:<br />In a study comparing the effects of levocetirizine 5 mg, desloratadine 5 mg, and placebo on<br />histamine-induced wheal and flare, levocetirizine treatment resulted in significantly decreased<br />wheal and flare formation which was highest in the first 12 hours and lasted for 24 hours,<br />(p&lt;0.001) compared with placebo and desloratadine.<br />The onset of action of levocetirizine 5 mg in controlling pollen-induced symptoms has been<br />observed at 1 hour post drug intake in placebo controlled trials in the model of the allergen<br />challenge chamber.<br />In vitro studies (Boyden chambers and cell layers techniques) show that levocetirizine inhibits<br />eotaxin-induced eosinophil transendothelial migration through both dermal and lung cells. A<br />pharmacodynamic experimental study in vivo (skin chamber technique) showed three main<br />inhibitory effects of levocetirizine 5 mg in the first 6 hours of pollen-induced reaction,<br />compared with placebo in 14 adult patients: inhibition of VCAM-1 release, modulation of<br />vascular permeability and a decrease in eosinophil recruitment.</p><p><u>Clinical efficacy and safety</u><br />The efficacy and safety of levocetirizine has been demonstrated in several double-blind,<br />placebo controlled, clinical trials performed in adult patients suffering from seasonal allergic<br />rhinitis, perennial allergic rhinitis, or persistent allergic rhinitis. Levocetirizine has been shown<br />to significantly improve symptoms of allergic rhinitis, including nasal obstruction in some<br />studies.<br />A 6-month clinical study in 551 adult patients (including 276 levocetirizine-treated patients)<br />suffering from persistent allergic rhinitis (symptoms present 4 days a week for at least 4<br />consecutive weeks) and sensitized to house dust mites and grass pollen demonstrated that<br />levocetirizine 5 mg was clinically and statistically significantly more potent than placebo on<br />the relief from the total symptom score of allergic rhinitis throughout the whole duration of the<br />study, without any tachyphylaxis. During the whole duration of the study, levocetirizine<br />significantly improved the quality of life of the patients.<br />In a placebo-controlled clinical trial including 166 patients suffering from chronic idiopathic<br />urticaria, 85 patients were treated with placebo and 81 patients with levocetirizine 5 mg once<br />daily over six weeks. Treatment with levocetirizine resulted in significant decrease in pruritus<br />severity over the first week and over the total treatment period as compared to placebo.<br />Levocetirizine also resulted in a larger improvement of health-related quality of life as assessed<br />by the Dermatology Life Quality Index as compared to placebo.<br />Chronic idiopathic urticaria was studied as a model for urticarial conditions. Since histamine<br />release is a causal factor in urticarial diseases, levocetirizine is expected to be effective in</p><p>providing symptomatic relief for other urticarial conditions, in addition to chronic idiopathic<br />urticaria.<br />ECGs did not show relevant effects of levocetirizine on QT interval.</p><p><u>Paediatric population</u><br />The paediatric safety and efficacy of levocetirizine tablets has been studied in two placebo<br />controlled clinical trials including patients aged 6 to 12 years and suffering from seasonal and<br />perennial allergic rhinitis, respectively. In both trials, levocetirizine significantly improved<br />symptoms and increased health-related quality of life.<br />In children below the age of 6 years, clinical safety has been established from several short- or<br />long -term therapeutic studies:</p><p>- one clinical trial in which 29 children 2 to 6 years of age with allergic rhinitis were treated<br />with levocetirizine 1.25 mg twice daily for 4 weeks<br />- one clinical trial in which 114 children 1 to 5 years of age with allergic rhinitis or chronic<br />idiopathic urticaria were treated with levocetirizine 1.25 mg twice daily for 2 weeks<br />- one clinical trial in which 45 children 6 to 11 months of age with allergic rhinitis or chronic<br />idiopathic urticaria were treated with levocetirizine 1.25 mg once daily for 2 weeks<br />- one long-term (18 months) clinical trial in 255 levocetirizine - treated atopic subjects aged 12<br />to 24 months at inclusion<br />The safety profile was similar to that seen in the short-term studies conducted in children 1 to 5<br />years of age.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of levocetirizine are linear with dose- and time-independent with low<br />inter-subject variability. The pharmacokinetic profile is the same when given as the single<br />enantiomer or when given as cetirizine. No chiral inversion occurs during the process of<br />absorption and elimination.<br /><u>Absorption</u><br />Levocetirizine is rapidly and extensively absorbed following oral administration. In adults,<br />peak plasma concentrations are achieved 0.9 h after dosing. Steady state is achieved after two<br />days. Peak concentrations are typically 270 ng/ml and 308 ng/ml following a single and a<br />repeated 5 mg o.d. dose, respectively. The extent of absorption is dose-independent and is not<br />altered by food, but the peak concentration is reduced and delayed.</p><p><u>Distribution</u><br />No tissue distribution data are available in humans, neither concerning the passage of<br />levocetirizine through the blood-brain-barrier. In rats and dogs, the highest tissue levels are<br />found in liver and kidneys, the lowest in the CNS compartment.<br />In humans, levocetirizine is 90% bound to plasma proteins. The distribution of levocetirizine is<br />restrictive, as the volume of distribution is 0.4 l/kg.</p><p><u>Biotransformation</u></p><p>The extent of metabolism of levocetirizine in humans is less than 14% of the dose and<br />therefore differences resulting from genetic polymorphism or concomitant intake of enzyme<br />inhibitors are expected to be negligible. Metabolic pathways include aromatic oxidation, Nand<br />O- dealkylation and taurine conjugation. Dealkylation pathways are primarily mediated by<br />CYP 3A4 while aromatic oxidation involved multiple and/or unidentified CYP isoforms.<br />Levocetirizine had no effect on the activities of CYP isoenzymes 1A2, 2C9, 2C19, 2D6, 2E1<br />and 3A4 at concentrations well above peak concentrations achieved following a 5 mg oral<br />dose.<br />Due to its low metabolism and absence of metabolic inhibition potential, the interaction of<br />levocetirizine with other substances, or vice-versa, is unlikely.</p><p><u>Elimination</u></p><p>The plasma half-life in adults is 7.9 &plusmn; 1.9 hours. The half-life is shorter in small children. The<br />mean apparent total body clearance in adults is 0.63 ml/min/kg. The major route of excretion of<br />levocetirizine and metabolites is via urine, accounting for a mean of 85.4% of the dose.<br />Excretion via faeces accounts for only 12.9% of the dose. Levocetirizine is excreted both by<br />glomerular filtration and active tubular secretion.</p><p><u>Special population</u></p><p><em>Renal impairment:</em><br />The apparent body clearance of levocetirizine is correlated to the creatinine clearance. It is<br />therefore recommended to adjust the dosing intervals of levocetirizine, based on creatinine<br />clearance in patients with moderate and severe renal impairment. In anuric end stage renal<br />disease subjects, the total body clearance is decreased by approximately 80% when compared<br />to normal subjects. The amount of levocetirizine removed during a standard 4-hour<br />hemodialysis procedure was &lt; 10%.<br /><em>Paediatric population:</em><br />Data from a paediatric pharmacokinetic study with oral administration of a single dose of 5 mg<br />levocetirizine in 14 children age 6 to 11 years with body weight ranging between 20 and 40 kg<br />show that Cmax and AUC values are about 2-fold greater than that reported in healthy adult<br />subjects in a cross-study comparison. The mean Cmax was 450 ng/ml, occurring at a mean<br />time of 1.2 hours, weight-normalized, total body clearance was 30% greater, and the<br />elimination half-life 24% shorter in this paediatric population than in adults. Dedicated<br />pharmacokinetic studies have not been conducted in paediatric patients younger than 6 years of<br />age. A retrospective population pharmacokinetic analysis was conducted in 323 subjects (181<br />children 1 to 5 years of age, 18 children 6 to 11 years of age, and 124 adults 18 to 55 years of<br />age) who received single or multiple doses of levocetirizine ranging from 1.25 mg to 30 mg.<br />Data generated from this analysis indicated that administration of 1.25 mg once daily to<br />children 6 months to 5 years of age is expected to result in plasma concentrations similar to<br />those of adults receiving 5 mg once daily.</p><p><em>Elderly</em><br />Limited pharmacokinetic data are available in elderly subjects. Following once daily repeat<br />oral administration of 30 mg levocetirizine for 6 days in 9 elderly subjects (65&ndash;74 years of<br />age), the total body clearance was approximately 33% lower compared to that in younger<br />adults. The disposition of racemic cetirizine has been shown to be dependent on renal function<br />rather than on age. This finding would also be applicable for levocetirizine, as levocetirizine<br />and cetirizine are both predominantly excreted in urine. Therefore, the levocetirizine dose<br />should be adjusted in accordance with renal function in elderly patients.</p><p><em>Gender</em><br />Pharmacokinetic results for 77 patients (40 men, 37 women) were evaluated for potential effect<br />of gender. The half-life was slightly shorter in women (7.08 &plusmn; 1.72 hr) than in men (8.62 &plusmn;<br />1.84 hr); however, the body weight-adjusted oral clearance in women (0.67 &plusmn; 0.16 ml/min/kg)<br />appears to be comparable to that in men (0.59 &plusmn; 0.12 ml/min/kg). The same daily doses and<br />dosing intervals are applicable for men and women with normal renal function.</p><p><em>Race</em><br />The effect of race on levocetirizine has not been studied. As levocetirizine is primarily renally<br />excreted, and there are no important racial differences in creatinine clearance, pharmacokinetic<br />characteristics of levocetirizine are not expected to be different across races. No race-related<br />differences in the kinetics of racemic cetirizine have been observed.</p><p><em>Hepatic impairment</em><br />The pharmacokinetics of levocetirizine in hepatically impaired subjects have not been tested.<br />Patients with chronic liver diseases (hepatocellular, cholestatic, and biliary cirrhosis) given 10<br />or 20 mg of the racemic compound cetirizine as a single dose had a 50% increase in half life<br />along with a 40% decrease in clearance compared to healthy subjects.</p><p><u>Pharmacokinetic / pharmacodynamic relationship</u><br />The action on histamine-induced skin reactions is out of phase with the plasma concentrations.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety<br />pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to<br />reproduction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose Monohydrate</p><p>Maize Starch<br />Colloidal Silicon Dioxide<br />Magnesium Stearate<br />Sunset Yellow<br />Excipients with known effect: 65.0mg Lactose Monohydrate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Layal </strong>tablets are packaged in PVC/ PVDC clear aluminium foil blisters.<br />Pack sizes of: 10 and 30 tablets</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jordan Sweden Medical and Sterilization Company (JOSWE-medical)
P.O. Box 851831 Amman 11185 Jordan
E-mail: joswe@go.com.jo
Head office: Sweifyeh.
Tel: +962 6 5859765 - + 962 6 5812748
Fax: +962 6 5814526
Fax: +962 6 5728326
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                04/2017.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>